Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Biomarkers

A biomarker and antibody technology, applied in the field of biomarkers, can solve problems such as low therapeutic effect

Inactive Publication Date: 2015-02-25
NAT CANCER CENT
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, it is known that there are patients with high therapeutic effect and patients with low therapeutic effect on chemoradiotherapy for cancer

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Biomarkers
  • Biomarkers
  • Biomarkers

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0052] [Example 1] This example shows that the therapeutic effect of chemoradiotherapy on cancer tissue is related to the survival rate of patients.

[0053] In the Pediatric Department of Digestive Organ Surgery, Tokyo Medical University Hospital, 37 patients with progressive esophageal squamous cell carcinoma underwent preoperative chemoradiotherapy, and esophagectomy was performed 4 weeks later. For chemotherapy, fluorouracil and CDDP are used, and for radiation therapy, electron beams are irradiated through a Linac (Linac accelerator).

[0054] In addition, chemoradiation therapy was continued for 4 weeks, continuously from the first day to the fifth day of each week. Daily administration of fluorouracil (5-FU, Kyowa Hakko Kirin Co., Ltd.) 350mg / m 2 (Patient body surface area), CDDP (Nippon Kayaku) 5mg / m 2 (Patient's body surface area), a total of 7000mg / m was administered separately during the entire treatment period 2 and a total of 100mg / m 2 . In addition, 2Gy of r...

Embodiment 2

[0065] [Example 2] This example shows that the therapeutic effect of chemoradiotherapy can be predicted by biomarkers sIL6R, MIP-1β and PAI-1.

[0066] Three biomarkers of sIL6R, MIP-1β, and PAI-1 were measured by fluorescent microsphere analysis system Luminex (Hitachi Software Co., Ltd.) or sandwich ELISA method in blood collected from the above-mentioned patients with esophageal squamous cell carcinoma before chemoradiation therapy thing.

[0067] Assay by fluorescent microsphere analysis system Luminex

[0068] The determination of sIL6R used Biosource’s Extracelular Luminex Kit sIL6R (product number LHR0061), the determination of MIP-1β used Biosource’s Extracelular Luminex Kit MIP-1β (product number LHC1051), and the determination of PAI-1 used R&D’s PAI-1, Human, Fluorokine MAP kit (Product No. LOB1359), commissioned analysis in Hitachi Software.

[0069] figure 2 A and B show the sIL6R concentration in each patient group of grades 1, 2, and 3, and the sIL6R concent...

Embodiment 3

[0078] [Example 3] This example shows that the prognosis of patients can be predicted by the biomarkers of the present invention.

[0079] Regarding the sIL6R concentration measured by the fluorescent microsphere analysis system or the sandwich ELISA method in Example 2, 30 ng / ml was used as the threshold value. At this time, for the high sIL6R population whose blood concentration is higher than the threshold value and the low sIL6R population whose blood concentration is lower than the threshold value, the graphs showing the survival rate up to 6 years or 9 years after the start of treatment are shown in Figure 6 and Figure 7 middle.

[0080] In the measurement by the fluorescent microsphere analysis system, 18 cases were judged to be in the high sIL6R group, and 19 cases were judged to be in the low sIL6R group. The 6-year survival rate was about 25% in the high sIL6R group compared with about 90% in the low sIL6R group, which was significantly higher (P=0.0012, long-ran...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

An object of the present invention is to provide biomarkers for predicting response to chemoradiotherapy for cancer and predicting prognosis of a patient with cancer, as well as methods of measuring such biomarkers. The response to chemoradiotherapy for cancer in a vertebrate animal can be predicted by measuring concentrations of a soluble interleukin-6 receptor, MIP-1², and an activated plasminogen activator inhibitor in the blood obtained from that individual with cancer before treatment with chemoradiotherapy, and prognosis of the same vertebrate animal can be determined by measuring a concentration of soluble interleukin-6 receptor.

Description

technical field [0001] The present invention relates to biomarkers for judging the suitability of chemoradiation therapy for cancer patients. Background technique [0002] In patients with adenocarcinoma and squamous cell carcinoma, improved cancer survival rates have been reported by chemoradiation therapy prior to tumor removal surgery compared with surgery alone (see, for example, Thomas N. et al., New England Journal of Medicine, 1996 Aug, 15:462-467 and Val Gebski et al., Lancet Oncol., 2007 Mar, 8(3):226-234). However, it is known that there are patients with high therapeutic effects and patients with low therapeutic effects of chemoradiotherapy for cancer. If these patients can be identified before treatment is implemented, the treatment method for the patients can be selected. Contents of the invention [0003] The problem to be solved by the invention [0004] Accordingly, an object of the present invention is to provide biomarkers for predicting the therapeuti...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): G01N33/574G01N33/68G01N33/53
CPCG01N33/57484G01N2333/5412G01N2333/8132G01N33/6869G01N2333/523G01N2333/7155G01N2800/52
Inventor 本田一文山田哲司幕内洋介逢坂由昭广桥说雄
Owner NAT CANCER CENT
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com